• / Free eNewsletters & Magazine
  • / My Account

High Risk

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)

  2. Fitch Affirms CIBC's Registered Covered Bonds at 'AAA'; Outlook Stable

    Fitch Affirms CIBC's Registered Covered Bonds at 'AAA'; Outlook Stable

  3. Goldman Banker Warned Colleagues Not to 'Milk Libya'

    Goldman Banker Warned Colleagues Not to 'Milk Libya'

  4. Cerenis Therapeutics: Cash Position and Revenue for the 1st Semester of 2016

    Cerenis Therapeutics: Cash Position and Revenue for the 1st Semester of 2016

  5. Goldman Banker Warned Colleagues Not to 'Milk Libya'

    Goldman Banker Warned Colleagues Not to 'Milk Libya'

  6. Delaware Investments® Dividend and Income Fund, Inc. Announces Change to Portfolio Management Team

    Delaware Investments® Dividend and Income Fund, Inc. Announces Change to Portfolio Management Team

  7. Cheap Exposure to Small-Growth Stocks

    This ETF's significant cost advantage should translate into attractive category-relative performance.

  8. This is your last chance to sell high-yield bonds

    This is your last chance to sell high-yield bonds

  9. PrEP Update: The Facts Speak for Themselves, Notes AHF

    PrEP Update: The Facts Speak for Themselves, Notes AHF

  10. SynerMed Receives Molina Healthcare’s 2016 Innovative Award for Demonstrating Excellence in Clinical Management and Effective Partnership for Its Downtown Coordinated Care Center

    SynerMed Receives Molina Healthcare’s 2016 Innovative Award for Demonstrating Excellence in Clinical Management and Effective Partnership for Its Downtown Coordinated Care Center

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.